Sleep-related hypermotor epilepsy
MONDO:0100631A focal epilepsy syndrome with characteristic brief motor seizures occurring from sleep. This syndrome was previously known as nocturnal frontal lobe epilepsy, and (when familial) autosomal dominant nocturnal frontal lobe epilepsy. It has both genetic and structural causes. Patients may have hyperkinetic seizures, or seizures with asymmetric dystonic/tonic motor features. The term sleep-related hyperkinetic epilepsy is to be used when patients have hyperkinetic seizures alone.
Also known as: SHE, nocturnal frontal lobe epilepsy, sleep-related hyperkinetic epilepsy
9 clinical trials for this condition and its sub-types, 0 tagged with Sleep-related hypermotor epilepsy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Sleep-related hypermotor epilepsy
-
5 sub-types
- Autosomal dominant nocturnal frontal lobe epilepsy 1 0 trials
- Autosomal dominant nocturnal frontal lobe epilepsy 2 0 trials
- Autosomal dominant nocturnal frontal lobe epilepsy 3 0 trials
- Autosomal dominant nocturnal frontal lobe epilepsy 4 0 trials
- Autosomal dominant nocturnal frontal lobe epilepsy 5 0 trials
-
Real-World study tracks Epidyolex's Long-Term impact on seizures
Disease control OngoingThis study follows 158 people in France who are prescribed Epidyolex (a cannabidiol-based medicine) for seizures as part of their normal care. Researchers will track how long people stay on the treatment, side effects, seizure frequency, and changes in daily functioning and quali…
Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New inhaler aims to stop prolonged seizures fast and safely
Symptom relief By invitation onlyThis study tests the long-term safety of an inhaled medication called Staccato alprazolam for people aged 12 and older who have prolonged seizures. About 300 participants will use the inhaler when a seizure starts to see if it stops the seizure quickly and without serious side ef…
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC